Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction

American Journal of Cardiology

Volumn 94, Issue 1, 2004, Pages 108-111

  Gibson, C Michael ^a,b   Bigelow, Brian ^a   James, David ^a   Tepper, Micah R ^a   Murphy, Sabina A ^a   Kirtane, Ajay J ^a   Giugliano, Robert P ^a   Cannon, Christopher P ^a   Antman, Elliott M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b TIMI Data Coordinating Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; FIBRINOLYTIC AGENT; TENECTEPLASE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CARDIOGENIC SHOCK; CARDIOVASCULAR SYMPTOM; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYSIS; HEART INJURY; HEART MUSCLE PERFUSION; HIGH RISK POPULATION; HUMAN; INTRACARDIAC THROMBOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; ST SEGMENT ELEVATION; SURGICAL MORTALITY; THROMBOSIS PREVENTION; TREATMENT INDICATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY;

EID: 3042654871     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.03.038     Document Type: Article

References (20)

1. Ryan T.J., Faxon D.P., Gunnar R.M., Kennedy J.W., King S.B. III, Loop F.D., Peterson K.L., Reeves T.J., Williams D.O., Winters W.L. Jr, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation. 78:1988;486-502
2. Ellis S.G., Vandormael M.G., Cowley M.J., DiSciascio G., Deligonul U., Topol E.J., Bulle T.M. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation. 82:1990;1193-1202
3. Myler R.K., Shaw R.E., Stertzer S.H., Hecht H.S., Ryan C., Rosenblum J., Cumberland D.C., Murphy M.C., Hansell H.N., Hidalgo B. Lesion morphology and coronary angioplasty current experience and analysis. J Am Coll Cardiol. 19:1992;1641-1652
4. Wilensky R.L., Selzer F., Johnston J., Laskey W.K., Klugherz B.D., Block P., Cohen H., Detre K., Williams D.O. Relation of percutaneous coronary intervention of complex lesions to clinical outcomes (from the NHLBI Dynamic Registry). Am J Cardiol. 90:2002;216-221
5. Harrell L., Schunkert H., Palacios I.F. Risk predictors in patients scheduled for percutaneous coronary revascularization. Catheter Cardiovasc Interv. 48:1999;253-260
6. Cannon C.P., Gibson C.M., McCabe C.H., Adgey A.A., Schweiger M.J., Sequeira R.F., Grollier G., Giugliano R.P., Frey M., Mueller H.S., et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 98:1998;2805-2814
7. Antman E.M., Giugliano R.P., Gibson C.M., McCabe C.H., Coussement P., Kleiman N.S., Vahanian A., Adgey A.A., Menown I., Rupprecht H.J., et al. Abciximab facilitates the rate and extent of thrombolysis results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation. 99:1999;2720-2732
8. Antman E.M., Louwerenburg H.W., Baars H.F., Wesdorp J.C., Hamer B., Bassand J.P., Bigonzi F., Pisapia G., Gibson C.M., Heidbuchel H., et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation. 105:2002;1642-1649
9. Giugliano R.P., Roe M.T., Harrington R.A., Gibson C.M., Zeymer U., Van de Werf F., Baran K.W., Hobbach H.P., Woodlief L.H., Hannan K.L., et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction results of the Integrilin and Tenecteplase in Acute Myocardial Infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol. 41:2003;1251-1260
10. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 312:1985;932-936
11. Gibson C.M., Cannon C.P., Daley W.L., Dodge J.T. Jr, Alexander B. Jr, Marble S.J., McCabe C.H., Raymond L., Fortin T., Poole W.K., Braunwald E. TIMI frame count a quantitative method of assessing coronary artery flow. Circulation. 93:1996;879-888
12. Gibson C.M., Cannon C.P., Murphy S.A., Ryan K.A., Mesley R., Marble S.J., McCabe C.H., Van De Werf F., Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 101:2000;125-130
13. Gibson C.M., Sandor T., Stone P.H., Pasternak R.C., Rosner B., Sacks F.M. Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trials. Am J Cardiol. 69:1992;1286-1290
14. STATA Statistical Software: Release 7.0. College Station, TX: STATA Corp., 2002
15. Zaacks S.M., Allen J.E., Calvin J.E., Schaer G.L., Palvas B.W., Parrillo J.E., Klein L.W. Value of the American College of Cardiology/American Heart Association stenosis morphology classification for coronary interventions in the late 1990s. Am J Cardiol. 82:1998;43-49
16. Kastrati A., Schomig A., Elezi S., Dirschinger J., Mehilli J., Schuhlen H., Blasini R., Neumann F.J. Prognostic value of the modified American College of Cardiology/American Heart Association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation. 100:1999;1285-1290
17. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961
18. Thel M.C., Califf R.M., Tcheng J.E., Sigmon K.N., Lincoff A.M., Topol E.J., Ellis S.G. Clinical risk factors for ischemic complications after percutaneous coronary interventions results from the EPIC trial. The EPIC Investigators. Am Heart J. 137:1999;264-273
19. Kleiman N.S., Rodriguez A.R., Raizner A.E. Interobserver variability in grading of coronary arterial narrowings using the American College of Cardiology/American Heart Association grading criteria. Am J Cardiol. 69:1992;413-415
20. Krone R.J., Shaw R.E., Klein L.W., Block P.C., Anderson H.V., Weintraub W.S., Brindis R.G., McKay C.R. Evaluation of the American College of Cardiology/American Heart Association and the Society for Coronary Angiography and Interventions lesion classification system in the current "stent era" of coronary interventions (from the ACC-National Cardiovascular Data Registry). Am J Cardiol. 92:2003;389-394